RNA seq transcriptomes of MASH patient isolated primary hepatocytes treated with Livogrit
Our previous studies revealed that Livogrit treatment can mitigate steatosis, phospholipidosis, and hepatic injury in various in-vitro and in-vivo models. This study was performed ex-vivo, on MASH patient isolated primary hepatocytes, where they were treated with Livogrit (100 ug/ml) after which their differential transcriptomic profile was analyzed.